Peyronie's Disease Articles

Articles

  • Inflatable Penile Prosthesis Placement, "Scratch Technique", and Postoperative Vacuum Therapy as a Combined Approach in the Definitive Treatment of Patients with Peyronie's Disease.

    Peyronie's disease (PD) is a devastating condition resulting in penile deformity, erectile dysfunction (ED), pain and emotional distress. This prospective two institution study evaluates a multimodal surgical and mechanical combined approach in the definitive treatment of PD and concomitant ED.

    Published April 22, 2018
  • Inhibition of penile tunica albuginea myofibroblasts activity by adipose-derived stem cells.

    The activation of tunica albuginea myofibroblasts (MFs) serves an essential role in Peyronie's disease (PD). Increasing evidence has reported that adipose tissue-derived stem cells (ADSCs) have been demonstrated to attenuate the symptoms of PD in animal models.

    Published December 13, 2017
  • Intralesional collagenaseClostridium histolyticumin the management of Peyronie's disease: current best practice.

    The use ofClostridium histolyticumcollagenase (CCH) has become increasingly widespread for the treatment of Peyronie's disease (PD) in recent years. Numerous trials have confirmed both its safety and efficacy in appropriately selected patients with this condition.

    Published March 24, 2018
  • Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie's Disease: Preliminary Results From a Prospective, Multicenter, Pilot Study.

    INTRODUCTION - Hyaluronic acid has been shown to be efficacious in decreasing scar formation, inflammation, and oxidative stress.

    AIM - To assess the efficacy of intralesional injection of hyaluronic acid in patients affected by Peyronie's disease.

    Published March 21, 2016
  • Levels of serum trace elements in patients with Peyronie.

    The etiology of the disease of Peyronie is not certainly known. However, penile micro traumas are thought to be important in the pathogenesis of Peyronie's disease (PD) in genetically predisposed individuals.

    Published June 2, 2018
  • Malleable Penile Implant Is an Effective Therapeutic Option in Men With Peyronie's Disease and Erectile Dysfunction.

    The inflatable penile prosthesis (IPP) is typically the preferred implant for Peyronie's disease (PD) and malleable penile prostheses (MPPs) have been discouraged.

    To evaluate the effectiveness and patient satisfaction of the MPP vs IPP in patients with PD.

    Published January 21, 2018
  • Management of Peyronie's disease with collagenase Clostridium histolyticum in the acute phase.

    Peyronie's disease (PD) can affect men of all ages and is associated with penile pain as well as curvature and erectile dysfunction. Treatment modalities for PD include conservative, less invasive and surgical treatments.

    Published May 19, 2019
  • Managing complications of collagenase Clostridium histolyticum (CCH) injection.

    The introduction of collagenase Clostridium histolyticum (CCH) has revolutionized the treatment of Peyronie's disease. The efficacy of this therapy has been well demonstrated and the safety profile is favorable.

    Published July 7, 2019
  • Multi-institutional prospective analysis of intralesional injection of Collagenase Clostridium Histolyticum, tunical plication and partial plaque excision and grafting for the management of Peyronie's disease.

    To compare in a prospective, non-randomized fashion the outcomes of Collagenase Clostridium Histolyticum (CCH) and surgical interventions (tunical plication [TP] and partial plaque excision and grafting [PEG]) in patients with PD.

    Published August 4, 2018
  • Negative Self-Perception and Self-Attitude of Sexuality Is a Risk Factor for Patient Dissatisfaction Following Penile Surgery with Small Intestinal Submucosa Grafting for the Treatment of Severe Peyronie's Disease.

    To assess patient satisfaction with surgical outcome, body related self-perceptions, self-attitudes of sexuality, and health related quality of life after penile surgery with small intestinal submucosa (SIS) grafting for the treatment of severe Peyronie's disease (PD).

    Published August 4, 2019
  • New Developments in Surgical Treatment for Penile Size Preservation in Peyronie's Disease.

    Peyronie's disease (PD) is associated with penile length loss due to atrophy that occurs as a result of fibrous inelastic scarring. Studies have shown diminished penile length and girth, as well as the inability to participate in sexual activity, can lead to decreased quality of life, emotional challenges, and sexual dissatisfaction in a large percentage of men.

    Published October 19, 2018
  • Non-invasive treatment in the management of Peyronie's disease.

    Peyronies disease (PD) is estimated to affect approximately 3-9% of men worldwide and maybe associated with pain, erectile dysfunction and penile deformity including shortening. The condition has significant debilitating effects on quality of life, self-esteem and psychological wellbeing in addition to sexual function.

    Published February 24, 2019
  • Objective Assessments of Peyronie's Disease.

    Penile deformity is the most obvious manifestation of Peyronie's disease (PD) and key to determining the optimal method of treatment. Other aspects of PD to consider include plaque size, location, and density; amount of calcification; erection quality; disease progression; and penile anatomy.

    Published March 5, 2018
  • Optimizing collagenase Clostridium histolyticum therapy for Peyronie's disease using a novel approach with percutaneous needle tunnelling.

    To compare the efficacy and safety of a combined treatment of percutaneous needle tunnelling (PNT) and a modified collagenase Clostridium histolyticum (CCH) protocol (PNT/CCH) vs the modified protocol alone (CCH) in the treatment of Peyronie's disease (PD).

    Published July 14, 2019
  • Outcomes of Surgery in Peyronie's Disease Following Intralesional Collagenase Clostridium Histolyticum Injections.

    To explore the potential hurdles surgeons may encounter when preforming surgical correction of penile curvature in patients with Peyronie's Disease following intralesional collagenase clostridium histolyticum injections.

    Published June 30, 2019
  • Outcomes of Surgical Management of Men with Peyronie's Disease with Hourglass Deformity.

    OBJECCTIVE - To investigate the outcomes of two surgical interventions for Peyronie's disease (PD) with hourglass deformity: partial excision and grafting (PEG) or inflatable penile prosthesis (IPP) implantation.

    Published February 23, 2016
  • Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease.

    Peyronie's disease (PD) is a debilitating affliction for the male population, causing severe curvatures to the erect penis and erectile dysfunction in about 50% of men. This deviation of the penis significantly impairs sexual intercourse and causes depression and strains in the relationship.

    Published May 5, 2019
  • Patient-reported long-term sexual outcomes following plication surgery for penile curvature: A retrospective 58-patient study.

    To evaluate long-term sexual function results following plication surgery for the correction of penile curvature using patient questionnaires.

    We performed a single-center, retrospective study in a cohort of patients with Peyronie's disease or congenital penile curvature.

    Published November 29, 2016
  • Penile lengthening with porcine small intestinal submucosa grafting in Peyronie's disease treatment: long-term surgical outcomes, patients' satisfaction and dissatisfaction predictors.

    Peyronie's Disease (PD) is an acquired connective tissue disorder that often leads to penile curvature (PC) and sexual dysfunction. Penile lengthening procedures (PLP) with four-layered porcine small intestinal submucosa graft (Surgisis® ES; Cook) have been widely used in patients with severe PC when erectile function is preserved.

    Published August 12, 2018
  • Penile ossification of the entire penile shaft found incidentally on pelvic x-ray.

    Penile ossification, a rare condition, has been linked traditionally to Peyronie's disease (PD) despite the presence of other less common etiologies. The ossification takes place usually in the mid-shaft of the penis with few cases reporting involvement of the entire shaft.

    Published August 4, 2019
  • Penile Plication With or Without Degloving of the Penis Results in Similar Outcomes.

    Penile plication techniques with or without degloving offer a minimally invasive option for the treatment of penile curvature.

    To review the outcomes of penile plication surgery and patient satisfaction with and without degloving of the penis.

    Published July 28, 2017
  • Penile Prosthesis Implantation in Patients With Peyronie's Disease: Results of the PROPPER Study Demonstrates a Decrease in Patient-Reported Depression.

    Although there is a strong correlation between erectile dysfunction and Peyronie's disease (PD), there are limited data on the efficacy and satisfaction of inflatable penile prosthesis (IPP) placement in this population.

    Published April 15, 2018
  • Penile Reconstructive Surgery in Peyronie Disease: Challenges in Restoring Normal Penis Size, Shape, and Function.

    To provide an overview of current approaches to penile reconstructive surgery in Peyronie disease (PD), and to discuss the challenges in restoring normal penile size and function.

    A systematic literature search was conducted to identify the published literature relevant to PD and penile reconstructive surgery.

    Published April 7, 2018
  • Penile Sensory Changes After Plaque Incision and Grafting Surgery for Peyronie's Disease.

    Plaque incision and grafting (PIG) for Peyronie's disease (PD) is not devoid of complications such as erectile dysfunction and penile sensory changes.

    To define the rate and chronology of penile sensation loss after PIG surgery and to define predictors of such.

    Published September 10, 2018
  • Penile Size Restoration With Nondegloving Approach for Peyronie's Disease: Initial Experience.

    The sliding technique (ST), commonly done with a subcoronal circumcising incision with penile degloving, has been used to restore penile size in patients with severe Peyronie's disease (PD) and erectile dysfunction, but with a potential risk of ischemic injury to the glans penis.

    Published September 13, 2018
  • Penile Stretching as a Treatment for Peyronie's Disease: A Review.

    Peyronie's disease (PD) is a debilitating condition that affects a sizable number of men worldwide. Current treatment options consist of oral therapy, intralesional injections, and surgery. Penile stretching has been used as a treatment for PD, including penile traction therapy (PTT) and vacuum erection devices (VEDs), with numerous trials completed or underway.

    Published January 13, 2019
  • Peyronie's Disease

    History and Background:

    • The first description of Peyronie's disease is credited to Francois Gigot de la Peyronie in 1743.
    • No consensus exists with regard to the etiology, prevalence and treatment of the condition.  
    • Peyronie's disease is associated with Dupuytren disease. Dupuytren disease has a familial pattern known to be transmitted in an autosomal dominant pattern. 
    • Thirty percent to 40% of men with Peyronie's disease will also have Dupuytren disease.

    Eitiology and Natual History:

    • Peyronie's disease presents as a variety of deformities of the penis. 
    • The symptomatic incidence has been estimated at 1%, but data indicates that the incidence is increasing and now can be estimated conservatively at 5% and some recent estimates are  8.9% to 13%.
    • Peyronie’s disease is defined by the presence of an inflammatory reaction and eventual fibrotic plaque development within the tunica albuginea or of the corpora cavernosa.
    • This plaque, which is palpable on physical examination in established cases, is associated with the common presenting symptoms of Peyronie’s disease, including pain with erection, curvature or deformity of the erect penis and erectile dysfunction (ED).
    • Plaque formation is thought to be the result of trauma, to the erect or semi-erect penis, which is propagated by aberrant would healing.
    • Reports of an association between Peyronie’s disease and Dupuytren’s contracture, plantar fascial contracture, tympanosclerosis, diabetes, urethral instrumentation, autoimmune disorders and as an inherited form of the disorder suggest that a multifactorial etiology is likely.
    • Disease development is described in two phases. 
      • The first phase is associated with painful erections and changing deformity of the penis. 
      • The second phase,is characterized by the disappearance of painful erections, if previously present, and a stability in the disease process.
    • Most patients do not require surgery. 
    • Patient's do require reassurance and education. 
    • Surgery for Peyronie's disease is considered palliation for the mechanical effects of the disease.
    • Peyronie's disease has been related to a number of conditions. The strongest relation is to Dupuytren disease.
    • The development of Peyronie's disease does seem to be related to the unique anatomy of the tunica albuginea and its relationship to the septal fibers.
    • Buckling trauma of the penis, usually occurring during intercourse, has been implicated in the development of Peyronie's disease. 
    • TGF-β has been found to be related to the disordered healing process that leads to the scarring of the Peyronie's plaque. 
    • Failure of downregulation of a number of “antifibrotic” factors has been implicated.

    Symptoms:

    • The presenting symptoms of Peyronie's disease include, in many patients, penile pain with erection; penile deformity, both flaccid and erect; shortening with and without an erection; plaque or indurated areas in the penis; and, in many patients, erectile dysfunction. 
    • On physical examination, virtually all patients have either a well-defined plaque or an area of induration that is palpable. 
    • The plaque is usually on the dorsal surface of the penis, intimately associated with the insertion of the septal fibers.
    • Spontaneous improvement in pain virtually always occurs as the inflammation resolves.

    Patient Evaluation:

    • Patients with Peyronie's disease present with a variety of deformities of the penis. 
    • Most have noted an indurated area in the penis that has been identified as the plaque. 
    • Many patients have noticed erectile dysfunction. 
    • All patients must be evaluated with a medical history, as well as a detailed psychosexual history. 
    • Approximately one third of the patients will develop dystrophic calcification in the plaque that can be demonstrated by ultrasonography or plain radiography. 
    • The place for MRI in the evaluation of Peyronie's plaque has not been defined, nor has the place for vascular testing been clearly defined. 
    • However, most urologists would agree that in patients who are to be operated on, vascular testing to stratify the vascular parameters of erectile function is a necessity. 
    • Once all of the data have been assembled, individualization with regard to the patient's requirements, findings, and assessment is imperative.

    Medical Management:

    • The efficacy of medical management of Peyronie's disease is difficult to determine because there are few RCT. 
    • Vitamin E has been used historically, and while supplementation has been studied for decades, and some success has been reported in older trials, those results have not been reproducible in RCT.
    • A combination of Vitamin E and colchicine has shown some promise in delaying progression of the condition.
    • Potassium aminobenzoate, in a small study, was found to reduce plaque size, not curvature, and thus in that study was found “efficacious.” However, the side effects make it difficult to tolerate.
    • A number of intralesional protocols have been proposed. 
    • The use of verapamil as an intralesional agent has been studied. A prospective study did show decrease in curvature in about 80% of the patients. 
    • Injections to plaques (scar tissue formed by the inflammation) with Verapamil may be effective in some patients, but a recent placebo controlled trial failed to show a significant improvement. 
    • So there are conflicting outcomes reported.
    • Interferon-alpha-2b has been proposed in recent publications.
    • Radiation therapy should be avoided. 
    • The vacuum erection device has not been adequately studied.
    • Penile traction has not been adequately studied.
    • The place of extracorporeal shockwave therapy has likewise not been adequately determined.

    The use of collagenase as an intralesional agent has been subjected to a number of double-blind placebo-controlled protocols, and, in all, efficacy was suggested. Collagenase is currently not available as an approved treatment and remains in development.  

    Surgery:

    • The consensus committee on Peyronie's disease at the World Health Organization Second International Consultation on Sexual Dysfunctions stated that the penile prosthesis is a reliable option for the older man with vascular impairment, erectile dysfunction, and acquired deformity of the penis.
    • It is not the only treatment of Peyronie's disease but rather a prudent treatment for the patient with significant erectile dysfunction in association with Peyronie's disease. 
    • Hydraulic prostheses are preferred, and those prostheses that have true controlled expansion cylinders have been shown to provide better results.

    References:

    • Brock G, Lue TF: Peyronie's disease, a modified treatment. Urology 1993; 42:300-304.
    • Brock G, Hsu GL, Nunes L, et al: The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J Urol 1997; 157:276-281.
    • Carson CC, Jordan GH, Gelbard MK: Peyronie's disease: new concepts in etiology, diagnosis and treatment. Contemp Urol 1999; 11:44-64.
    • Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. Adva Urol 2011;282503.
    • Hellstrom WJ: History, epidemiology and clinical presentation of Peyronie's disease [review]. Int J Impot Res 2003; 15(Suppl.):S91-S92. S121-4.
    • Levine LA, Greenfield JM: Establishing a standardized evaluation of the man with Peyronie's disease [review]. Int J Impot Res 2003; 15(Suppl.):S103-S112.
    • Levine LA. Peyronie's disease and erectile dysfunction: Current understanding and future direction. Indian J Urol 2006;22:246-50.
    • Mulhull JP, Creech SD, Boorjian SA, et al: Subjective and objective analysis of the prevalence of peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004; 171:2350 - 53.
    • Mynderse LA, Monga M (October 2002). "Oral therapy for Peyronie's disease". International Journal of Impotence Research 14 (5): 340–4.
    • Nyberg Jr LM, Bias WB, Hochbert MC, Walsh PC: Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens. J Urol 1982; 128:48-51.
    • O’Brien K, Parker M, Guhring P, et al: Analysis of the natural history of Peyronie's disease [abstract 69]. J Sex Med 2004; 1(Suppl. 1):50.
    • Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, et al: Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int 2003; 91:522-524.
    • Riedl CR, Sternig P, Gallé G, et al. (October 2005). "Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study". European Urology 48 (4): 656–61.
    • Trost LW, Gur S, Hellstrom WJ (2007). "Pharmacological Management of Peyronie's Disease". Drugs 67 (4): 527–45.
    Published October 1, 2014
  • Peyronie's disease and Dupuytren's contracture secondary to topical timolol.

    Topical beta-blockers are a proven and safe medication used in the treatment of glaucoma and ocular hypertension. Local and systemic side effects are, however, well documented. Systemic side effects can include severe cardio-respiratory impairment, endocrine dysfunction, as well as headache and hyper-somnolence.

    Published February 12, 2018
  • Peyronie's disease and testosterone deficiency: Is there a link?

    Peyronie's disease (PD) and testosterone deficiency (TD) impact men at the same stage of life and can ultimately contribute to erectile dysfunction. There is speculation that low levels of testosterone (T) may predispose men to penile fibrosis; however, there is no published, up-to-date review summarizing the current evidence.

    Published March 17, 2019
  • Peyronie's disease: What's around the bend?

    INTRODUCTION - Peyronie's disease (PD) is a fibrotic diathesis of the tunica albuginea that results in penile plaque formation and penile deformity, negatively affecting sexual and psychosocial function of both patients and their partners.

    Published March 30, 2016
  • Phase I and phase II clinical trials for the treatment of male sexual dysfunction - A systematic review of the literature.

    Introduction - The prevalence of sexual dysfunctions has increased over the last decades; despite a number of available treatments for erectile dysfunction (ED), premature ejaculation (PE) and Peyronie's disease (PD), still several unmet therapeutic needs deserve to be fulfilled.

    Published July 9, 2018
  • Plaque calcification: An important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie's Disease.

    To compare outcomes of men with or without calcified plaques undergoing collagenase clostridium histolyticum (CCH) injections for Peyronie's Disease (PD) and identify predictors of CCH success.

    From March 2014 through January 2017, data were prospectively collected on 192 patients who underwent 1-4 cycles of CCH for the treatment of PD.

    Published June 26, 2018
  • Plication for Severe Peyronie's Deformities Has Similar Long-Term Outcomes to Milder Cases.

    Penile plication (PP) for Peyronie's disease (PD) is an established treatment option for mild to moderate curvature, but scant data exist regarding its utility in severe deformities.

    To evaluate long-term outcomes among men undergoing PP for PD, comparing severe to mild/moderate penile deformities.

    Published September 29, 2018
  • Practical Computerized Solution for Incision and Grafting in Peyronie's Disease.

    INTRODUCTION - Penile curvature correction with plaque incision and graft (PIG) increases the risk of erectile dysfunction (ED) and is associated with mechanical and geometric abnormalities.

    AIMS - The aim of this study was to create and validate a new PIG technique using minimum graft area to correct simple or complex penile curvature with or without hourglass deformity, while avoiding mechanical and geometric abnormalities.

    Published January 26, 2016
  • Prospective study to evaluate the clinical outcome of intralesional interferon-α2b in the management of Peyronie's disease.

    Interferon (IFN)-α2b in Peyronie's disease (PD).

    This study aims to evaluate clinical efficacy of the IFN-α2b in both subjective and objective manner for the treatment of PD and compared with previously used intralesional verapamil in terms of cost-benefit analysis.

    Published May 6, 2018
  • Reduction in Peyronie's-like plaque size using a vacuum erection device in a rat model of Peyronie's disease via the TGF-β/SMAD signalling pathway.

    Peyronie's disease (PD) is a fibrotic disorder of the tunica albuginea (TA). This study aimed to determine the therapeutic effects of a vacuum erection device (VED) in an animal model of PD and explore the possible mechanisms.

    Published July 1, 2018
  • Review of Management Options for Active-Phase Peyronie's Disease.

    Peyronie's disease (PD) is a fibrotic disorder that leads to plaque formation in ∼3-9% of adult men. Connective tissue buildup results in plaque formation, penile curvature and shortening, and in some cases, pain.

    Published December 9, 2018
  • Review of Management Options for Patients With Atypical Peyronie's Disease.

    Peyronie's disease (PD) is a wound-healing disorder of the tunica albuginea often associated with penile deformity. Less commonly, patients with PD might display atypical presentations such as ventral curvature, hourglass deformity, significantly shortened penis, and/or multiplanar curvature.

    Published September 6, 2016
  • Role of extracorporeal shock wave therapy in management of Peyronie's disease: A preliminary report.

    Peyronie's Disease (PD) is a disease causing psycho social trauma to the patient. Multiple treatment options are available with variable results. Extra Corporeal Shock Wave Therapy (ESWT) is a new insight into the non invasive modality of management.

    Published January 9, 2017
  • Safety Profile of Collagenase Clostridium Histolyticum Stratified by Degree of Penile Curvature in Patients with Peyronie's Disease.

    To examine the safety of collagenase clostridium histolyticum (CCH) in adult males with penile curvature deformity <30°. Collagenase clostridium histolyticum is indicated for treatment of Peyronie's disease (PD) in adult males with palpable plaque and a penile curvature deformity ≥30° at start of therapy; however, during treatment, patients may receive CCH injections when penile curvature deformity is <30°.

    Published May 21, 2017
  • Satisfaction of patients with Peyronie's disease after plaque surgery and bovine pericardium graft.

    Plaque and bovine pericardium graft surgery is a useful tool for treating Peyronie's disease.

    To determine patient satisfaction following this operation.

    This was a retrospective, observational and descriptive study.

    Published August 2, 2016
  • Separating the Wheat From the Chaff: An Evaluation of Readability, Quality, and Accuracy of Online Health Information for Treatment of Peyronie's Disease.

    To characterize available information about Peyronie's disease online and evaluate its readability, quality, accuracy, and respective associations with HONcode certification and website category.

    The search term "Peyronie's disease" was queried on three major search engines (Google, Bing, Yahoo) and the first 50 search results on each search engine were assessed.

    Published May 7, 2018
  • Shockwave Therapy in the Treatment of Peyronie's Disease.

    Peyronie's disease is an acquired condition of the connective tissue of the penis that affects 0.5-20.3% of the male population and is marked by fibrotic plaques in the tunica albuginea. It can result in penile curvature/deviation, painful erections, and sexual dysfunction.

    Published March 31, 2019
  • Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis.

    The effectiveness of phosphodiesterase type 5 (PDE5) inhibitors over the conservative management of Peyronie's disease (PD) has been widely questioned.

    To determine the role of sildenafil 25 mg film formulation twice a day (S25 b.

    Published October 6, 2018
  • Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie's disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation.

    To uncover the anti-myofibroblast (MFB) properties of Rho-kinase inhibitor (compound Y-27632) and simvastatin in an in vitro model of Peyronie's disease (PD), a sexually debilitating disease caused by an irreversible fibrotic plaque in the penile tunica albuginea (TA).

    Published March 10, 2019
  • Small Intestinal Submucosa Grafting for Peyronie's Disease: Outcomes and Patient Satisfaction.

    To evaluate surgical outcomes and complications and assess overall patient satisfaction after small intestinal submucosa (SIS) grafting for PD.

    Twenty-eight patients were treated with tunical incision and grafting with SIS.

    Published November 15, 2016
  • Sub-Coronal Inflatable Penile Prosthesis Placement With Modified No-Touch Technique: A Step-by-Step Approach With Outcomes.

    INTRODUCTION = The surgical treatment of disorders of male sexual function requires specific exposure to correct the underlying problem safely and efficiently. Currently, sub-coronal exposure is used for treatment of phimosis, Peyronie's disease plaque (PDP), and semirigid penile prosthesis insertion.

    Published February 23, 2016
  • Successful Treatment of Residual Curvature in Peyronie's Disease in Men Previously Treated with Intralesional Collagenase Clostridium Histolyticum.

    To determine the success and feasibility of surgically correcting residual curvature after intralesional collagenase Clostridium histolyticum (CCH) for the treatment of Peyronie's disease.

    We performed a retrospective analysis of patients who had intralesional CCH treatment for (PD) and who subsequently underwent penile plication (PP), plaque incision and grafting (PIG), or inflatable penile prosthesis (IPP) placement.

    Published September 10, 2017
  • Supporting the role of penile trauma and micro-trauma in the etiology of Peyronie's disease. Prospective observational study using the electronic microscope to examine two types of plaques.

    The etiopathogenesis of Peyronie's disease (PD) remains not clearly understood. The most accepted theory attributes the histological lesions of PD to the effects of trauma to the corpora cavernosum of the penis.

    Published April 7, 2019
  • Surgical Outcomes of Plaque Excision and Grafting and Supplemental Tunica Albuginea Plication for Treatment of Peyronie's Disease With Severe Compound Curvature.

    There are limited data in the literature that describe the management of Peyronie's disease (PD) with severe compound curvature, which often requires additional straightening procedures after plaque excision and grafting (PEG) to achieve functional penile straightening (<20 degrees).

    Published June 26, 2018

Page 2 of 3

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe